PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2017

Conditions
Breast Cancer
Interventions
DRUG

Lapatinib

DRUG

Trastuzumab

DRUG

Endocrine Therapy

Letrozole or tamoxifen will be prescribed according to patient's menopausal status

DRUG

Paclitaxel

Only administrated if tumor progression is observed by US on week 6

Trial Locations (22)

10003

Hospital San Pedro de Alcántara, Cáceres

28041

Hospital Universitario 12 de Octubre, Madrid

46800

Hospital Luis Alcanyís de Xàtiva, Xàtiva

Unknown

Hospital de Torrevieja, Torrevieja

Hospital Son Llàtzer, Palma de Mallorca

Hospital Universitario Son Espases, Palma de Mallorca

Institut Català d'Oncologia Hospitalet, L'Hospitalet de Llobregat

Hospital Mutua de Terrassa, Terrassa

Consorcio Hospitalario Provincial de Castellón, Castellon

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

Hospital Universitario de Fuenlabrada, Fuenlabrada

Hospital Universitario Virgen de la Arrixaca, El Palmar

Hospital Universitario Sant Joan de Reus, Reus

Hospital Clínic de Barcelona, Barcelona

Instituto Dexeus, Barcelona

Hospital Universitario Arnau de Vilanova de Lleida, Lleida

Hospital Clínico San Carlos, Madrid

Hospital Universitario Ramón y Cajal, Madrid

Hospital Clínico Universitario de Valencia, Valencia

Hospital Universitario Arnau de Vilanova de Valencia, Valencia

06071

Hospital Universitario Infanta Cristina, Badajoz

08035

Vall d'Hebron University Hospital, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

SOLTI Breast Cancer Research Group

OTHER